Cost-effectiveness of a multicomponent-adherence intervention in fracture liaison services
Expert Review of Pharmacoeconomics & Outcomes Research · 2024
DOI: 10.1080/14737167.2024.2366439 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2024. Verfasst von Lieke Maas und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Services research, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands. Hauptthemen laut MEDLINE: Cost-Benefit Analysis, Quality-Adjusted Life Years, Markov Chains, Motivational Interviewing. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ZonMw research line Rational Pharmacotherapy.
Abstract (Originalsprache)
BACKGROUND: This study aims to assess the lifetime cost-effectiveness of a multi-component adherence intervention (MCAI), including a patient decision aid and motivational interviewing, compared to usual care in patients with a recent fracture attending fracture liaison services (FLS) and eligible for anti-osteoporosis medication (AOM). RESEARCH DESIGN AND METHODS: Data on AOM initiation and one-year persistence were collected from a quasi-experimental study conducted between 2019 and 2023 in two Dutch FLS centers. An individual level, state-transition Markov model was used to simulate lifetime costs and quality-adjusted life years (QALYs) with a societal perspective of MCAI vs usual care. One-way and probabilistic sensitivity analyses were conducted including variation in additional FLS and MCAI costs (no MCAI cost in baseline). RESULTS: MCAI was associated with gain in QALYs (0.0012) and reduction in costs (-€16) and is therefore dominant. At the Dutch willingness-to-pay threshold of €50,000/QALY, MCAI remained cost-effective when increasing costs of the FLS visit or the yearly maintenance cost for MCAI up to +€60. Probabilistic sensitivity analysis demonstrated MCAI to be dominant in 54% of the simulations and cost-effective in 87% with a threshold of €50,000/QALY. CONCLUSIONS: A MCAI implemented in FLS centers may lead to cost-effective allocation of resources in FLS care, depending on extra costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health Services research, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands.
- Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands.
- Department of Internal Medicine, VieCuri Medical Center, Venlo, The Netherlands.
- Department of Internal Medicine, NUTRIM, Maastricht University Medical Center, Maastricht, The Netherlands.
ORCID-Profile: Lieke Maas, Annelies Boonen, Nannan Li, Caroline E Wyers, Joop P Van den Bergh, Mickaël Hiligsmann
Förderung
- ZonMw research line Rational Pharmacotherapy
Zitieren
APA
Maas, L., Boonen, A., Li, N., Wyers, C. E., Van den Bergh, J. P., & Hiligsmann, M. (2024). Cost-effectiveness of a multicomponent-adherence intervention in fracture liaison services. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2024.2366439
Vancouver
Maas L, Boonen A, Li N, Wyers CE, Van den Bergh JP, Hiligsmann M. Cost-effectiveness of a multicomponent-adherence intervention in fracture liaison services. Expert Review of Pharmacoeconomics & Outcomes Research. 2024. doi:10.1080/14737167.2024.2366439
BibTeX
@article{Maas2024,
author = {Maas, Lieke and Boonen, Annelies and Li, Nannan and Wyers, Caroline E and Van den Bergh, Joop P and Hiligsmann, Mickaël},
title = {Cost-effectiveness of a multicomponent-adherence intervention in fracture liaison services},
journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
year = {2024},
doi = {10.1080/14737167.2024.2366439}
}
EUVIMED